Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
New England Journal of Medicine May 22, 2019 Jean Kim, Tiffany R. Farchione, Andrew Potter et al.
The FDA has approved esketamine as a new antidepressant for treatment-resistant depression. The drug offers a rapid onset of action, a key advantage for patients who have not responded to other treatments. The approval followed an evaluation of the drug's benefits and risks by the agency.